Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins

Angela Dispenzieri, Robert A. Kyle, Morie A. Gertz, Terry M. Therneau, Wayne L. Miller, Krishnaswamy Chandrasekaran, Joseph P. McConnell, Mary F. Burritt, Allan S. Jaffe

Research output: Contribution to journalArticlepeer-review

242 Scopus citations


Patients with primary systemic amyloidosis that affects the heart have a poor outlook. Cardiac troponins T and I (cTnT, cTnI) are highly specific and sensitive biomarkers of myocardial injury. Values of these troponins provide quantitative information about the disease. We retrospectively assessed 261 patients newly diagnosed as having primary systemic amyloidosis. Median survival for patients with detectable cTnT and cTnI (6 and 8 months, respectively), was worse than that for those with undetectable values (22 and 21 months, respectively). Median and 25th and 75th percentile values for cTnT were 0.024 μg/L, less than 0.01 μg/L, and 0.084 μg/L, and for cTnI were 0.1 μg/L, 0.05 μg/L, and 0.24 μg/L, respectively. After multivariate analysis, cTnT proved a better predictor of survival than cTnI.

Original languageEnglish (US)
Pages (from-to)1787-1789
Number of pages3
Issue number9371
StatePublished - May 24 2003

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins'. Together they form a unique fingerprint.

Cite this